Table 4.
Summary of potential cross-reactive immunity to SARS-CoV-2 from selected vaccine antigens.
| Vaccine Antigens | Proteins | SARS-Peptide Hits(1) | B(2) | CD8 T(3) | CD4 T(4) |
|---|---|---|---|---|---|
| D | 340 | 24 | 6 | 5 | 2 |
| T | 601 | 28 | 13 | 8 | 2 |
| aP | 25 | 3 | 1 | 1 | 0 |
| wP | 1,852 | 67 | 23 | 10 | 5 |
| MenB | 267 | 10 | 3 | 2 | 1 |
1Number of peptides in the relevant antigens with ≥8 residues and identity ≥80% with SARS-CoV-2. 2Peptide hits with B cell reactivity ≥0.4 (predicted as cross-reactive B cell epitopes). 3Peptides predicted as cross-reactive CD8 T cell epitopes. 4Peptides predicted as cross-reactive CD4 T cell epitopes. Whole dataset available in Supplementary Dataset 2.